 Arvinas Inc NASDAQ: ARVN announced the presentation of new data from completed Phase 1 dose-escalation and ongoing Phase 2 ARDENT expansion cohort with bavdegalutamide ARV-110. The data were shared at the 2022 American Society of Clinical Oncology Genitourinary ASCO GU Cancers Symposium. 